The new plant will be adjacent to West's injection molding facility that was dedicated in September 2009.
When completed, the plant will manufacture components used for pharmaceutical packaging, supplying customers primarily in China and the Asia-Pacific region. The 11,900-square-meter facility is expected to begin production in January 2013.
“West is experiencing an exciting period of growth in the Asia-Pacific region and we are proud to begin our second manufacturing facility in China,” said Donald E. Morel, Jr., West's Chairman and Chief Executive Officer. “This facility is being established to provide better service to our customers in China, offering shorter lead times for delivery of our world-class pharmaceutical packaging products and creating new, flexible capacity to meet the growing needs of new customers in China and throughout the Asia-Pacific region. Our investment in this new facility demonstrates our commitment to and confidence in the China market.
“On behalf of West's Board of Directors and our employees worldwide, I would like to thank representatives of the Chinese government and the Shanghai Qingpu Industrial Zone, in particular, for their continued support throughout the process of planning the new facility.”
In addition to the injection molding plant in Qingpu, West's presence in the Asia-Pacific region includes a factory in Singapore and sales offices in Australia, China, India and Singapore. West is also an equity partner of Daikyo Seiko, Ltd., Tokyo, Japan. Daikyo Seiko, founded in 1954, is a global leader in manufacturing ultra-clean pharmaceutical packaging and medical device components. The West/Daikyo relationship has been in place since 1973, encompassing a range of joint distributorship and technology licensing agreements.
When completed, the plant will manufacture components used for pharmaceutical packaging, supplying customers primarily in China and the Asia-Pacific region. The 11,900-square-meter facility is expected to begin production in January 2013.
“West is experiencing an exciting period of growth in the Asia-Pacific region and we are proud to begin our second manufacturing facility in China,” said Donald E. Morel, Jr., West's Chairman and Chief Executive Officer. “This facility is being established to provide better service to our customers in China, offering shorter lead times for delivery of our world-class pharmaceutical packaging products and creating new, flexible capacity to meet the growing needs of new customers in China and throughout the Asia-Pacific region. Our investment in this new facility demonstrates our commitment to and confidence in the China market.
“On behalf of West's Board of Directors and our employees worldwide, I would like to thank representatives of the Chinese government and the Shanghai Qingpu Industrial Zone, in particular, for their continued support throughout the process of planning the new facility.”
In addition to the injection molding plant in Qingpu, West's presence in the Asia-Pacific region includes a factory in Singapore and sales offices in Australia, China, India and Singapore. West is also an equity partner of Daikyo Seiko, Ltd., Tokyo, Japan. Daikyo Seiko, founded in 1954, is a global leader in manufacturing ultra-clean pharmaceutical packaging and medical device components. The West/Daikyo relationship has been in place since 1973, encompassing a range of joint distributorship and technology licensing agreements.
Companies in this article
